Your browser doesn't support javascript.
loading
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura, Izumi; Yamasoba, Daichi; Tamura, Tomokazu; Nao, Naganori; Suzuki, Tateki; Oda, Yoshitaka; Mitoma, Shuya; Ito, Jumpei; Nasser, Hesham; Zahradnik, Jiri; Uriu, Keiya; Fujita, Shigeru; Kosugi, Yusuke; Wang, Lei; Tsuda, Masumi; Kishimoto, Mai; Ito, Hayato; Suzuki, Rigel; Shimizu, Ryo; Begum, Mst Monira; Yoshimatsu, Kumiko; Kimura, Kanako Terakado; Sasaki, Jiei; Sasaki-Tabata, Kaori; Yamamoto, Yuki; Nagamoto, Tetsuharu; Kanamune, Jun; Kobiyama, Kouji; Asakura, Hiroyuki; Nagashima, Mami; Sadamasu, Kenji; Yoshimura, Kazuhisa; Shirakawa, Kotaro; Takaori-Kondo, Akifumi; Kuramochi, Jin; Schreiber, Gideon; Ishii, Ken J; Hashiguchi, Takao; Ikeda, Terumasa; Saito, Akatsuki; Fukuhara, Takasuke; Tanaka, Shinya; Matsuno, Keita; Sato, Kei.
Afiliación
  • Kimura I; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yamasoba D; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Faculty of Medicine, Kobe University, Kobe, Japan.
  • Tamura T; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Nao N; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan.
  • Suzuki T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Oda Y; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Mitoma S; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
  • Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Nasser H; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Zahradnik J; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Fujita S; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Wang L; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Tsuda M; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Kishimoto M; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Ito H; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Suzuki R; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Shimizu R; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Begum MM; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Yoshimatsu K; Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Kimura KT; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Sasaki J; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Sasaki-Tabata K; Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
  • Yamamoto Y; HiLung Inc., Kyoto, Japan.
  • Nagamoto T; HiLung Inc., Kyoto, Japan.
  • Kanamune J; HiLung Inc., Kyoto, Japan.
  • Kobiyama K; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Asakura H; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Shirakawa K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kuramochi J; Interpark Kuramochi Clinic, Utsunomiya, Japan; Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan.
  • Schreiber G; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Ishii KJ; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hashiguchi T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan. Electronic address: hashiguchi.takao.1a@kyoto-u.ac.jp.
  • Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan. Electronic address: ikedat@kumamoto-u.ac.jp.
  • Saito A; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Center for Animal Disease Control, University of Miyazaki, Miyazaki, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan. Electronic address: sakatsuki@c
  • Fukuhara T; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Electronic address: fukut@pop.med.hokudai.ac.jp.
  • Tanaka S; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. Electronic address: tanaka@med.hokudai.ac.jp.
  • Matsuno K; One Health Research Center, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo,
  • Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University
Cell ; 185(21): 3992-4007.e16, 2022 10 13.
Article en En | MEDLINE | ID: mdl-36198317
After the global spread of the SARS-CoV-2 Omicron BA.2, some BA.2 subvariants, including BA.2.9.1, BA.2.11, BA.2.12.1, BA.4, and BA.5, emerged in multiple countries. Our statistical analysis showed that the effective reproduction numbers of these BA.2 subvariants are greater than that of the original BA.2. Neutralization experiments revealed that the immunity induced by BA.1/2 infections is less effective against BA.4/5. Cell culture experiments showed that BA.2.12.1 and BA.4/5 replicate more efficiently in human alveolar epithelial cells than BA.2, and particularly, BA.4/5 is more fusogenic than BA.2. We further provided the structure of the BA.4/5 spike receptor-binding domain that binds to human ACE2 and considered how the substitutions in the BA.4/5 spike play roles in ACE2 binding and immune evasion. Moreover, experiments using hamsters suggested that BA.4/5 is more pathogenic than BA.2. Our multiscale investigations suggest that the risk of BA.2 subvariants, particularly BA.4/5, to global health is greater than that of original BA.2.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enzima Convertidora de Angiotensina 2 / COVID-19 Límite: Humans Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enzima Convertidora de Angiotensina 2 / COVID-19 Límite: Humans Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Japón